Table 2.
Best response in full analysis set
| RECIST by investigators | irRECIST by investigators | RECIST by IRC | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| All patients | 124 | 124 | 124 | |||
| CR | 3 | 2.4 | 2 | 1.6 | 3 | 2.4 |
| PR | 19 | 15.3 | 19 | 15.3 | 10 | 8.1 |
| SD | 29 | 23.4 | 28 | 22.6 | 16 | 12.9 |
| PD | 58 | 46.8 | 60 | 48.4 | 50 | 40.3 |
| NE | 15 | 12.1 | 15 | 12.1 | 45 | 36.3 |
| ORR | 22 | 17.7 | 21 | 16.9 | 13 | 10.5 |
| 95% CI | 11.5–25.6% | 10.8–24.7% | 5.7–17.3% | |||
| DCR | 51 | 41.1 | 49 | 39.5 | 29 | 23.4 |
| 95% CI | 32.4–50.3% | 30.9–48.7% | 16.3–31.8% | |||
RECIST, Response Evaluation Criteria in Solid Tumours version 1.1; irRECIST, immune-related RECIST; IRC, independent radiology review committee; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; CI, confidence interval; ORR, objective response rate; DCR, disease control rate.